[go: up one dir, main page]

MX2018015483A - Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1). - Google Patents

Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1).

Info

Publication number
MX2018015483A
MX2018015483A MX2018015483A MX2018015483A MX2018015483A MX 2018015483 A MX2018015483 A MX 2018015483A MX 2018015483 A MX2018015483 A MX 2018015483A MX 2018015483 A MX2018015483 A MX 2018015483A MX 2018015483 A MX2018015483 A MX 2018015483A
Authority
MX
Mexico
Prior art keywords
dnmt1
relates
compound
treatment
sickle cell
Prior art date
Application number
MX2018015483A
Other languages
English (en)
Other versions
MX391600B (es
Inventor
Waszkowycz Bohdan
Anderson Evans Karen
M Jordan Allan
Li Mei
David Adams Nicholas
B Benowitz Andrew
Lourdes Rueda Benede Maria
T Fosbenner David
Wayne King Bryan
Ignacio Luengo Juan
Henry Miller William
Joseph Reif Alexander
Paul Romeril Stuart
J Schmidt Stanley
J Butlin Roger
M Goldberg Kristin
S Kershaw Christopher
Raoof Ali
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2018015483A publication Critical patent/MX2018015483A/es
Publication of MX391600B publication Critical patent/MX391600B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invencion se refiere a derivados de piridina sustituidos. Especificamente, la invencion se refiere a compuestos segun la formula (Iar): (ver fórmula) en donde Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar y R5ar son como se definen en la presente memoria; o una sal farmaceuticamente aceptable o profarmaco del mismo; los compuestos de la invencion son inhibidores selectivos de DNMT1 y pueden ser utiles en el tratamiento del cancer, sindromes precancerosos, trastornos de beta hemoglobinopatia, enfermedad de celulas falciformes, anemia de celulas falciformes y beta talasemia, y enfermedades asociadas con la inhibicion de DNMT1; por consiguiente, la invencion se refiere ademas a composiciones farmaceuticas que comprenden un compuesto de la invencion; la invencion se refiere ademas a metodos para inhibir la actividad de DNMT1 y al tratamiento de trastornos asociados con la misma, usando un compuesto de la invencion o una composicion farmaceutica que comprende un compuesto de la invencion.
MX2018015483A 2016-06-13 2017-06-13 Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1) MX391600B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662349227P 2016-06-13 2016-06-13
US201662393256P 2016-09-12 2016-09-12
US201662412343P 2016-10-25 2016-10-25
PCT/IB2017/053511 WO2017216727A1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1

Publications (2)

Publication Number Publication Date
MX2018015483A true MX2018015483A (es) 2019-03-18
MX391600B MX391600B (es) 2025-03-21

Family

ID=59239935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015483A MX391600B (es) 2016-06-13 2017-06-13 Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1)

Country Status (20)

Country Link
US (1) US10975056B2 (es)
EP (1) EP3468953B1 (es)
JP (1) JP7051829B2 (es)
KR (1) KR20190017030A (es)
CN (1) CN109563043B (es)
AU (1) AU2017283790B2 (es)
CA (2) CA3026211A1 (es)
CL (1) CL2018003577A1 (es)
CO (1) CO2018013717A2 (es)
CR (1) CR20180580A (es)
DO (1) DOP2018000273A (es)
ES (1) ES2993451T3 (es)
IL (1) IL263163B (es)
JO (1) JOP20180120A1 (es)
MA (1) MA45244A (es)
MX (1) MX391600B (es)
PE (1) PE20190971A1 (es)
PH (1) PH12018502633B1 (es)
SG (1) SG11201809559UA (es)
WO (2) WO2017216727A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2017027645A1 (en) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
CR20190168A (es) 2016-10-04 2019-05-17 Merck Sharp & Dohme Compuestos de benzo[b]tiofeno como agonistas de sting
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3774765A4 (en) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
WO2022076563A1 (en) * 2020-10-07 2022-04-14 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
AU2022230795B2 (en) 2021-03-02 2025-02-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN113278021B (zh) * 2021-05-29 2022-09-23 天津全和诚科技有限责任公司 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
CN114230459A (zh) * 2021-12-10 2022-03-25 武汉九州钰民医药科技有限公司 一种化合物的制备方法及分析检测方法
WO2023192629A1 (en) * 2022-04-01 2023-10-05 Herophilus, Inc. Induction of mecp2 expression by dna methyl transferase inhibitors
WO2024156288A1 (en) * 2023-01-29 2024-08-02 Shanghai Kygent Pharmaceutical Co., Ltd Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications
CN121368481A (zh) * 2023-06-29 2026-01-20 丹娜-法伯癌症研究院 用于降解dna甲基转移酶1 (dnmt1)的蛋白水解靶向嵌合体(protacs)的合成和体外表征
WO2025085756A1 (en) * 2023-10-18 2025-04-24 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
WO2025190285A1 (en) * 2024-03-12 2025-09-18 Shanghai Kygent Pharmaceutical Co., Ltd Pyridine compounds, pharmaceutical compositions, and applications
CN119306700A (zh) * 2024-08-28 2025-01-14 山东大学 Dnmt1-hdac双靶点抑制剂及其制备方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030875C (en) 1990-11-26 2002-07-02 Alan R.P. Paterson Methods and probes for detecting nucleoside transporter and method for producing the probes
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
ZA942125B (en) 1993-03-26 1994-11-10 Shell Res Ltd Herbicidal heterocyclic compounds.
CN1209063A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
BR9612378A (pt) 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores de vitronectina
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
AU2108601A (en) 1999-12-15 2001-06-25 Axys Pharmaceuticals, Inc. Salicylamides as serine protease inhibitors
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
US20030166554A1 (en) 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
TW200406370A (en) 2002-06-28 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives
TW200406152A (en) 2002-08-30 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy) phenol derivatives having pesticidal properties
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
TW200410632A (en) 2002-12-11 2004-07-01 Syngenta Participations Ag Dihalo-allyloxy-phenol derivatives having pesticidal activity
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
EP1610774A4 (en) 2003-04-09 2008-07-16 Exelixis Inc TIE-2 MODULATORS AND METHODS OF USE
CA2526361C (en) 2003-05-20 2012-05-15 Ajinomoto Co., Inc. Amide derivative
CN1856307A (zh) 2003-09-23 2006-11-01 默克公司 喹啉钾通道抑制剂
AU2011253934C1 (en) 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1655296A1 (en) 2004-10-25 2006-05-10 Graffinity Pharmaceuticals AG Thrombin inhibitors
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
AU2007262055A1 (en) 2006-06-20 2007-12-27 Ishihara Sangyo Kaisha, Ltd. Pest control agent containing novel pyridyl-methanamine derivative or salt thereof
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
WO2008093075A2 (en) 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009034433A2 (en) 2007-09-10 2009-03-19 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
EP2195304B1 (en) 2007-10-08 2014-01-08 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
WO2010020810A1 (en) 2008-08-19 2010-02-25 Astrazeneca Ab 2-(imidaz0lylamin0)-pyridine derivatives and their use as jak kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
KR101146010B1 (ko) * 2009-09-10 2012-05-16 서울대학교산학협력단 ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물
CN102686584A (zh) 2009-11-13 2012-09-19 盐野义制药株式会社 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物
US8440689B2 (en) 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
JP5793505B2 (ja) 2009-12-23 2015-10-14 ジャスコ ファーマシューティカルズ， エルエルシー アミノピリミジンキナーゼ阻害薬
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
WO2011103289A2 (en) 2010-02-17 2011-08-25 Jasco Pharmaceuticals, LLC Imidazole-2, 4-dione inhibitors of casein kinase 1
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CA2824808A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013019621A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2747560A4 (en) 2011-07-29 2015-02-25 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
EP2771012A4 (en) * 2011-10-24 2015-06-24 Glaxosmithkline Ip No 2 Ltd NEW CONNECTIONS
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US9914730B2 (en) 2012-09-28 2018-03-13 Cancer Research Technology Limited Azaquinazoline inhibitors of Atypical protein Kinase C
JP2017502968A (ja) 2014-01-21 2017-01-26 ウォックハート リミテッド ７−オキソ−１，６−ジアザビシクロ［３．２．１］オクタン誘導体及び抗菌剤としてのその使用
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof

Also Published As

Publication number Publication date
JOP20180120A1 (ar) 2019-01-30
EP3468953A1 (en) 2019-04-17
WO2017216726A1 (en) 2017-12-21
CA3026211A1 (en) 2017-12-21
SG11201809559UA (en) 2018-12-28
IL263163B (en) 2021-10-31
CN109563043B (zh) 2022-05-31
JP2019517596A (ja) 2019-06-24
CR20180580A (es) 2019-07-02
CA3026226A1 (en) 2017-12-21
MA45244A (fr) 2019-04-17
EP3468953C0 (en) 2024-05-22
US20190194166A1 (en) 2019-06-27
ES2993451T3 (en) 2024-12-30
PE20190971A1 (es) 2019-07-09
KR20190017030A (ko) 2019-02-19
CN109563043A (zh) 2019-04-02
EP3468953B1 (en) 2024-05-22
AU2017283790B2 (en) 2019-08-29
JP7051829B2 (ja) 2022-04-11
BR112018075992A2 (pt) 2019-04-02
PH12018502633A1 (en) 2019-09-30
CO2018013717A2 (es) 2019-01-18
CL2018003577A1 (es) 2019-04-05
PH12018502633B1 (en) 2023-02-01
IL263163A (en) 2018-12-31
US10975056B2 (en) 2021-04-13
AU2017283790A1 (en) 2018-11-22
WO2017216727A1 (en) 2017-12-21
MX391600B (es) 2025-03-21
DOP2018000273A (es) 2019-03-31

Similar Documents

Publication Publication Date Title
CO2018013717A2 (es) Piridinas sustituidas como inhibidores de dnmt1
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
HN2012001744A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
GT201200242A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY37028A (es) Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds
MX345763B (es) Nuevos macrociclos como inhibidores del factor xia.
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
CO6551666A2 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
CO6741217A2 (es) Modulares de receptor de glucagón
MX375484B (es) Derivados de azabencimidazol como inhibidores de pi3k beta
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
BR112018007128A2 (pt) compostos para a inibição de câncer e epigênese
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
AR089122A1 (es) Formulaciones orales para tratar la sobrecarga de metales
BR112013012665A2 (pt) composto de fórmula (i), ou um sal, pró-droga ou solvato do mesmo e composição farmacêutica
EA201990023A1 (ru) Замещенные пиридины в качестве ингибиторов dnmt1